Nirsevimab vs RSVpreF Vaccine for Newborn RSV Hospitalization Risk

Nirsevimab vs RSVpreF Vaccine for Newborn RSV Hospitalization Risk This research study evaluates the effectiveness of two preventative treatments used to protect newborns from respiratory syncytial virus (RSV). By comparing maternal vaccination during pregnancy with the direct administration of nirsevimab to infants, scientists sought to determine which method better prevents serious illness. The data indicates that nirsevimab significantly reduces the risk of hospital stays and the need for intensive care compared to the maternal vaccine. Furthermore, infants who received the monoclonal antibody treatment were less likely to require critical interventions like ventilator support or oxygen therapy. These findings provide crucial evidence for public health officials and pediatricians as they refine immunization strategies for future viral seasons.